Virus Specific T-Cell

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Virus Specific T-Cell
DrugBank Accession Number
DB15735
Background

Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. In some cases, the cells are created from blood samples of patients who have recovered from viral infections.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Autologous cell transplant / Other cell transplant therapies
Synonyms
  • HLA-matched Virus Specific T Cells
  • Partially HLA-matched Virus Specific T Cell
  • Viral Specific T-lymphocytes
  • VST
External IDs
  • Virus Specific T-Cell

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Administration of VSTs can provide physiological protection against specific infections, especially for patients who are immunocompromised and depleted of T-cells. VSTs are used as an immunotherapy against many infections, including Epstein-Barr virus, adenovirus, BK virus, and human herpesvirus type 6. This type of treatment is also being investigated as a therapy against SARS-Cov-2.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Houghtelin A, Bollard CM: Virus-Specific T Cells for the Immunocompromised Patient. Front Immunol. 2017 Oct 11;8:1272. doi: 10.3389/fimmu.2017.01272. eCollection 2017. [Article]
  2. Barrett AJ, Prockop S, Bollard CM: Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant. 2018 Jan;24(1):13-18. doi: 10.1016/j.bbmt.2017.10.004. Epub 2017 Oct 12. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnTreatmentCoronavirus Disease 2019 (COVID‑19) / Viral Infections1
1RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Viral Infections1
1, 2Active Not RecruitingTreatmentAdenovirus Infections / Cytomegalovirus (CMV) Infection / Epstein Barr Virus Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 20:16 / Updated on August 13, 2020 07:02